- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03833323
Implantable System for Remodulin Post-Approval Study (ISR PAS)
June 30, 2021 updated by: Medtronic Cardiac Rhythm and Heart Failure
The purpose of the Implantable System for Remodulin (ISR) Post Approval Study (PAS) is to provide evaluation and periodic reporting of the safety and effectiveness of Medtronic market-released ISR, including the catheter and the pump.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The ISR PAS is an observational, prospective, non-randomized, multi-center study.
It will enroll a minimum of 50 newly implanted patients at up to 10 US sites, observing and reporting catheter-related complications and pump failures through 5 years post implant.
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Newly implanted patients that are intended to receive an ISR.
Description
Inclusion Criteria:
- Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements.
- Subject is intended to receive an eligible ISR product.
- Subject is at least 22 years of age.
Exclusion Criteria:
- Subject is pregnant.
- Subject who is expected to be inaccessible for follow-up.
- Subject with exclusion criteria required by local law.
- Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results (i.e. no required intervention that could affect interpretation of all-around product safety and or effectiveness).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Catheter-related complications
Time Frame: Implant to 5 years post-implant
|
Number of adverse events requiring invasive intervention that are related to the ISR catheter.
|
Implant to 5 years post-implant
|
|
Pump failures
Time Frame: Implant to 5 years post-implant
|
Number of adverse events requiring invasive intervention that are related to the ISR pump.
|
Implant to 5 years post-implant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Robert Bourge, MD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2020
Primary Completion (Actual)
June 30, 2021
Study Completion (Actual)
June 30, 2021
Study Registration Dates
First Submitted
February 5, 2019
First Submitted That Met QC Criteria
February 5, 2019
First Posted (Actual)
February 7, 2019
Study Record Updates
Last Update Posted (Actual)
July 2, 2021
Last Update Submitted That Met QC Criteria
June 30, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISR PAS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension (PAH)Brazil
-
University Hospital, BrestNot yet recruitingPulmonary Arterial Hypertension (PAH)France
-
Shanghai Zhongshan HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Regeneron PharmaceuticalsRecruitingPulmonary Arterial Hypertension (PAH)United States, United Kingdom, Latvia, South Korea
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
Clinical Trials on Implantable System for Remodulin (treprostinil)
-
Medtronic Cardiac Rhythm and Heart FailureUnited TherapeuticsActive, not recruitingPulmonary Arterial HypertensionUnited States
-
United TherapeuticsWithdrawnPulmonary Arterial Hypertension
-
United TherapeuticsCompletedPulmonary Arterial Hypertension
-
United TherapeuticsTerminatedPeripheral Vascular Disease | Critical Limb Ischemia | Foot Ulcers | Rest Leg PainUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsCVie Therapeutics Co. Ltd.WithdrawnPulmonary Arterial HypertensionChina
-
ExcelsiorNot yet recruitingPulmonary Arterial Hypertension
-
Stanford UniversityTerminatedSingle VentricleUnited States
-
United TherapeuticsTerminatedPeripheral Vascular DiseaseUnited States
-
Magdi H. YacoubRecruitingPulmonary HypertensionEgypt